Lantheus
Valuation each multiple against its own 5-year range
Vs. peers Drug Manufacturers - Specialty & Generic
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Lantheus (LNTH) | 6.68B | 25.40 | 4.93 | 0.00% |
| Takeda Pharmaceutical (TAK) | 69.76B | 311.00 | 1.50 | 1.44% |
| Teva Pharmaceutical Industries (TEVA) | 45.77B | 91.23 | 5.74 | 0.00% |
| Haleon (HLN) | 39.76B | 19.14 | 1.85 | 2.09% |
| Zoetis (ZTS) | 32.14B | 13.34 | 9.73 | 2.64% |
| United Therapeutics (UTHR) | 23.63B | 20.94 | 3.76 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 10.8% above Morningstar's fair value estimate.
Fair value
Lantheus Holdings Inc is assigned a 2-star quantitative star rating, illustrating our stance that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 12% premium over our quantitative fair value estimate of $91.04 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.
The firm's unfavorable dividend structure undermines our valuation estimate. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. For example, the firm's forward dividend yield of 0% falls in the bottom 30% compared with peers globally. This could imply a planned dividend cut or relatively high share price, which contributes to our view that shares are overvalued.
The company's valuation metrics are an additional cause for concern. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 20.6%, a core component of valuation, lies in the bottom 20% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which further promotes our unfavorable price/fair value ratio.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.
Economic moat
The company's narrow economic moat rating suggests it should be able to maintain robust profitability for a decade or longer before competition erodes its advantage. Its moat is bolstered by its strong financial health, which indicates low near-term bankruptcy risk.
By Quantitative Equity Report
Quote time 2026-11-20 20:01:26 · For reference only, not investment advice and not tailored to your situation.
Lantheus discussion 0 comments